Below the Guideline's Cortisol Threshold: Hold the Steroid Taper or Continue It
A single patient whose steroid taper has stalled exactly at the point a 2024 guideline says to hold, against a newer study suggesting that threshold may be more conservative than the evidence now supports.
Harold B., a 68-year-old retired postal supervisor, has been on prednisone for polymyalgia rheumatica for two years, tapered slowly from an initial 20 mg down to his current 5 mg, with his rheumatologist confirming his underlying disease has been quiet for eight months and no longer needs treatment at all. He has taken to marking each dose reduction on the kitchen calendar his late wife used for garden planting, a habit their daughter noticed on a recent visit and found, she said, both practical and a little sad. What's stopped the taper at 5 mg is a morning cortisol drawn per the 2024 joint ESE/Endocrine Society guideline, which came back at 130 nmol/L — below the 150 nmol/L threshold that guideline treats as evidence the HPA axis hasn't recovered enough to taper further, with the explicit instruction to hold the physiologic dose and recheck again in weeks to months rather than continue reducing.
What complicates a simple "follow the guideline" answer is Mehta et al.'s 2026 retrospective cohort study in Endocrine Connections, published after the guideline itself, that followed sixty-five patients through exactly this kind of taper and found something the guideline's own threshold doesn't account for: continued reduction below 5 mg, done carefully and led by symptoms rather than halted by the cortisol number, was associated with rising — not falling — cortisol values as the dose came down further, and 42% of patients who successfully completed their taper had done so with a nadir morning cortisol under 150 nmol/L along the way, including six with values too low to detect. No adrenal crises occurred in that cohort. The study's own conclusion was blunt: physiological-dose tapering may promote HPA axis recovery rather than simply follow it, which is close to the opposite of what a strict reading of "don't taper below 150 nmol/L" assumes.
Rheumatology and endocrinology, joint taper review
The current joint guideline is explicit: below 150 nmol/L means hold the physiologic dose and recheck later, not taper further. I know his disease is quiet, but I'm not comfortable departing from a current, named threshold on the strength of one retrospective study that hasn't been folded into the standard yet.
I take the guideline seriously too, but the 2026 study followed patients in exactly his situation — physiologic-dose tapering below the threshold — and found cortisol values RISING as the dose came down, not falling toward crisis; 42% of successful weans had gone through a nadir below 150 on the way, with zero adrenal crises in that cohort. Harold has no active disease needing the steroid and a new borderline glucose that's plausibly from staying on it. I don't think "hold indefinitely" is obviously the safer choice here anymore.
I'm not saying ignore the guideline — I'm saying the newest, most directly relevant evidence complicates treating its threshold as an absolute floor rather than a general caution.
I don't think you two are as far apart as it sounds. Try a smaller step than a full push toward discontinuation — reduce by half a milligram rather than a full milligram, watch closely for any symptom at all, and recheck cortisol sooner than the guideline's usual "weeks to months" interval. That respects the real crisis risk the rheumatologist is protecting against and the real evidence the endocrinologist is citing, without either holding him on an unnecessary dose indefinitely or pushing a full taper attempt today.
Agreed: a small, half-milligram reduction with morning cortisol rechecked in three weeks and symptoms reviewed at every visit, rather than either holding indefinitely at 5mg or attempting a full taper today.
Not agreed: how the team should weigh the newer 2026 study against the current formal guideline going forward, beyond this one patient. The rheumatologist wants to wait for the guideline itself to be updated before treating the new evidence as a standing practice change; the endocrinologist would apply the same cautious-but-continued approach to other similar patients now, without waiting for a formal guideline revision.